Pulse Biosciences (PLSE) Free Cash Flow (2015 - 2025)

Pulse Biosciences' Free Cash Flow history runs 11 years deep, the most recent figure standing at -$14.9 million for Q4 2025.

• On a quarterly basis, Free Cash Flow fell 61.96% year-over-year to -$14.9 million in Q4 2025; TTM through Dec 2025 was -$54.4 million, a 49.66% decrease from a year earlier, with the FY2025 full-year figure at -$54.4 million, down 49.66% from the prior year.
• Free Cash Flow slipped to -$14.9 million in Q4 2025 per PLSE's latest filing, from -$13.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$6.6 million in Q1 2023 and bottomed at -$16.5 million in Q2 2021.
• The 5-year median for Free Cash Flow is -$11.2 million (2021), against an average of -$11.3 million.
• Across the five-year window, Free Cash Flow plunged 109.21% in 2021 and soared 57.69% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$12.4 million in 2021, then jumped by 35.53% to -$8.0 million in 2022, then climbed by 14.75% to -$6.8 million in 2023, then slumped by 34.43% to -$9.2 million in 2024, then plunged by 61.96% to -$14.9 million in 2025.
• Per Business Quant, the three latest PLSE Free Cash Flow figures stand at -$14.9 million (Q4 2025), -$13.2 million (Q3 2025), and -$12.8 million (Q2 2025).